nCounter® Analysis System
More insights from
Prosigna® Breast Cancer Prognostic Gene Signature Assay
Empowering personalized treatment decisions
Learn More *See product pages for regulatory status information
on actionable answers
David Coffey, MD, is a physician scientist with the Fred Hutchinson Cancer Research Center in Seattle, Washington. When he’s not treating patients, he’s in the lab researching blood cancers such as multiple myeloma and lymphoma. His research centers on the detection of circulating DNA in peripheral blood samples to identify mutations involved in these cancers. We recently spoke with Dr. Coffey about his research, the challenges he faces, and his vision for the future.
Robin Lynn White
November 15, 2017
nCounter® Analysis in Complex Biology:
Gene expression profile predicts response to pembrolizumab
A video review of JCI publication by Ayers, et al:
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Sarah Warren, Ph.D. and Patrick Danaher, Ph.D.
Transcriptional profiling of the tumor microenvironment can lead to insights about the interaction between the tumor and immune system. This facilitates investigation of immune evasion mechanisms, enables potential development of novel therapeutics, and allows for possible identification of responder/non-responder populations in immunotherapy research. The NanoString PanCancer IO 360™ Panel is a 770 target, multiplexed gene expression panel developed for characterization of expression patterns from the tumor, immune system, and stroma. It contains the Tumor Inflammation Signature, which includes 18 functional genes known to be associated with response to PD-1/PD-L1 inhibitors pathway blockade. The ...
Understanding the Heterogeneity, Dynamics and Spatial Interactions in Checkpoint Blockade Immunotherapy - NOV 29, 2017 9:00 AM PST
Alexandre Reuben, Ph.D. - Translational Immunologist, MD Anderson Cancer Center
Immune checkpoint blockade has shown tremendous promise in patients with melanoma, however responses remain heterogeneous. Therefore, better biomarkers are needed to identify who will benefit. Here, we studied a cohort of metastatic melanoma patient samples treated with CTLA-4 or PD-1 blockade. We performed molecular, immune, and Digital Spatial Profiling* in order to identify biomarkers of response and mechanisms of resistance to checkpoint blockade. Furthermore, we investigated the impact of tumor heterogeneity on differential responses to therapy in a subset of samples with synchronous melanoma metastases. These findings provide insights into differential responses to checkpoint blockade.
*For Research Use Only. Not for use in diagnostic procedures.
Deciphering the Complexity of the Acute Leukemia Immunological Microenvironment with 3D Biology™ Technology - DEC 05, 2017 9:00 AM PST
Doug Hinerfeld, Ph.D., Principal Product Application Scientist, NanoString Technologies; Sergio Rutella, M.D., Ph.D., Professor of Cancer Immunotherapy, John van Geest Cancer Research Centre, Nottingham Trent University
Therapeutic strategies in patients with acute myeloid leukemia (AML) have remained relatively unchanged over the last 30 years. The development and delivery of new therapeutic strategies for high-risk AML, including immunotherapy, therefore remains a priority. Tumor phenotypes are dictated not only by the neoplastic cell component, but ...